Journey East: How Chinese Returnees Build Global-Bound Biopharmas
From Money To Talent To Collaboration, Challenges Keep Coming
Executive Summary
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
You may also be interested in...
Hotter Than Oncology? China Immunology Players Raise $650m
The China bioventure sector is poised to set a record for initial public offerings and fundraising, but one therapeutic area is taking a surprise lead - immunology.
China mRNA Player Abogen Gets $300m More As Country Eyes Omicron Threat
From inactivated virus-based to mRNA platforms, the race is on in China to develop vaccines to fight the latest omicron variant, with substantial new funding pouring into one young mRNA company.
3D Med, Alphamab Get First SubQ Immuno-Oncology Approval, In China
A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.